Morgan Stanley upgraded Amicus (FOLD) to Overweight from Equal Weight with a $12 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus Therapeutics Advances Pediatric Fabry Disease Study with Migalastat
- Amicus Therapeutics Advances Pompe Disease Research with New Observational Study
- Amicus Therapeutics’ Migalastat Study: A Potential Game-Changer for Fabry Disease Treatment
- Amicus Therapeutics Expands Access to Migalastat for Fabry Disease Patients
- Amicus Therapeutics Completes Key Study on Pompe Disease Treatment Interactions